AstraZeneca PLC (AZN.L)
17 May 2013
|Market Cap (Mil.):||£42,611.12|
|Shares Outstanding (Mil.):||1,251.39|
LONDON - AstraZeneca has enrolled the first patient into a final-stage clinical trial of a new drug for a rare type of leukemia as the group's new CEO delivers on a promise to accelerate its oncology programs.
* Final-stage studies on olaparib, selumetinib start in H2
* Early-stage research but scientists see momentum building
LONDON, April 25 - Britain's top share index traded flat on Thursday, steadying after recent robust gains, with falls in stocks such as AstraZeneca and Unilever on weak corporate earnings pegging the market back.
LONDON - AstraZeneca's sales fell by a bigger-than-expected 13 percent in the first quarter as patent expiries took a heavy toll, underscoring the turnaround challenge facing Britain's second-largest drugmaker.
* Q1 sales fall 13 pct to $6.39 bln vs consensus $6.51 bln
LONDON - AstraZeneca said on Thursday it had received a subpoena from the U.S. Attorney's Office in Boston, Massachusetts, related to manufacturing standards at its Macclesfield facility in the north of England.
LONDON, April 25 - AstraZeneca said on Thursday it had received a subpoena from the U.S. Attorney's Office in Boston, Massachusetts, related to manufacturing standards at its Macclesfield facility in the north of England.
LONDON, April 25 - AstraZeneca's sales fell by a bigger-than-expected 13 percent in the first quarter as patent expiries sent revenue from key medicines skidding lower, underscoring the turnaround challenge facing Britain's second biggest drugmaker.
LONDON, April 22 - AstraZeneca is to pay privately held Bind Therapeutics as much as $200 million to develop a cancer medicine using the U.S. biotech company's nanotechnology drug delivery system.
Earnings vs. Estimates
Analyst Research Reports
Provider: Pechala's Reports
AstraZeneca PLC: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Thomson Reuters Stock Report
Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of ASTRAZENECA PLC -ADR including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation.
Provider: Jefferson Research
Provider: ValuEngine, Inc.
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.